After the Bell
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
The only sure things about 2009 are the recession and a new administration. So defensive issues and potential 'Obama plays' look interesting.
©1996-2016 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.